| MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study JM Mitchell, M Bogenschutz, A Lilienstein, C Harrison, S Kleiman, ... Focus 21 (3), 315-328, 2023 | 693 | 2023 |
| Rapid micro‐induction of buprenorphine/naloxone for opioid use disorder in an inpatient setting: a case series S Klaire, R Zivanovic, SP Barbic, R Sandhu, N Mathew, P Azar The American journal on addictions 28 (4), 262-265, 2019 | 109 | 2019 |
| A review of novel methods to support the transition from methadone and other full agonist opioids to buprenorphine/naloxone sublingual in both community and acute care settings SM Ghosh, S Klaire, R Tanguay, M Manek, P Azar Canadian Journal of Addiction 10 (4), 41-50, 2019 | 60 | 2019 |
| The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD CR Nicholas, JB Wang, A Coker, JM Mitchell, SS Klaire, B Yazar-Klosinski, ... Drug and alcohol dependence 233, 109356, 2022 | 48 | 2022 |
| α-linolenic acid and docosahexaenoic acid, alone and combined with trastuzumab, reduce HER2-overexpressing breast cancer cell growth but differentially regulate HER2 signaling … JK Mason, S Klaire, S Kharotia, AKA Wiggins, LU Thompson Lipids in Health and Disease 14, 1-10, 2015 | 46 | 2015 |
| Rapid transition from methadone to buprenorphine utilizing a micro-dosing protocol in the outpatient veteran affairs setting JP De Aquino, C Fairgrieve, S Klaire, G Garcia-Vassallo Journal of addiction medicine 14 (5), e271-e273, 2020 | 41 | 2020 |
| Rapid induction of buprenorphine/naloxone for chronic pain using a microdosing regimen: a case report DS Lee, JE Hann, SS Klaire, M Nikoo, MD Negraeff, P Rezazadeh-Azar A&A Practice 14 (2), 44-47, 2020 | 36 | 2020 |
| A low-barrier, flexible safe supply program to prevent deaths from overdose S Klaire, C Sutherland, T Kerr, MC Kennedy CMAJ 194 (19), E674-E676, 2022 | 29 | 2022 |
| Buprenorphine/naloxone induction for treatment of acute on chronic pain using a micro-dosing regimen: a case report R Sandhu, R Zivanovic, S Klaire, M Nikoo, J Rozylo, P Azar Canadian Journal of Pain 3 (1), 79-84, 2019 | 23 | 2019 |
| Take-home drug checking as a novel harm reduction strategy in British Columbia, Canada S Klaire, RM Janssen, K Olson, J Bridgeman, EE Korol, T Chu, C Ghafari, ... International Journal of Drug Policy 106, 103741, 2022 | 14 | 2022 |
| Safety and efficacy of rapid methadone titration for opioid use disorder in an inpatient setting: a retrospective cohort study S Klaire, N Fairbairn, A Ryan, S Nolan, M McLean, P Bach Journal of addiction medicine 17 (6), 711-713, 2023 | 4 | 2023 |
| Differential effect of cannabis use on opioid agonist treatment outcomes: exploratory analyses from the OPTIMA study L Elkrief, G Bastien, C McAnulty, H Bakouni, FO Hébert, ME Socias, ... Journal of Substance Use and Addiction Treatment 149, 209031, 2023 | 3 | 2023 |
| Navigating the “Psychedelic Renaissance”: From Research to Reality D Payer, S Klaire, D Morisano, M Bartram, M Williams, B Rush International Journal of Mental Health and Addiction 22 (2), 801-805, 2024 | 2 | 2024 |
| A perspective on psychedelics as treatments for addictions: Past, Present, and Future D Nutt, C Morgan, S Klaire Journal of Studies on Alcohol and Drugs, jsad. 23-00032, 2024 | 1 | 2024 |
| Characterizing the Use of Healthcare Access Supports Among People Who Use Drugs in Vancouver, Canada, 2017 to 2020: A Cohort Study K Hayashi, G Rabu, Z Cui, S Klaire, F Homayra, MJ Milloy, B Nosyk Substance Use & Addiction Journal, 29767342241249870, 2024 | | 2024 |
